| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Genelux Corporation$3.03
+0.05 (+1.68%)
C 43Pipeline Score Overvalued Pharma · Commercial
Market Cap
130.93 M
EPS
-0.85
P/E Ratio
-
Value Trade
898.50 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
5.78 M
Operating CF
-6.06 M
Total Assets
32.37 M
Total Liabilities
9.45 M
Equity
22.92 M
D/E Ratio
12,345
-2.34 %
Week
9.77 %
1 Month
9.77 %
3 Month
-36.66 %
6 Month
-51.33 %
5 Year
-51.33 %
All Time
Cash Data
Cash Position
26.17 M
Monthly Burn
2.02 M
Runway
11.1 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
248.65 K
52 Week Range
2.29 - 8.54
% held by Insiders
14.31 %
% held by Institutions
30.63 %
Enterprise Value
107.22 M
Total Shares
44.82 M
Short %
7.87 %
Float Shares
38.23 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genelux Corporation
116Total events
2Upcoming
19Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 2
Event history 114
Jun 30, 2026
▲PublicationOlvi-VecPresentation
Publication of translational analysis from VIRO-15 trial in Gynecologic Oncology Reports
platinum-resistant/refractory ovarian cancersource ↗
Q2 2026
◆Topline ReadoutOlvi-VecClinical Data
Topline data from Phase 3 OnPrime/GOG-3076 registrational trial
platinum-resistant/refractory ovarian cancersource ↗
Feb 18, 2026
Feb 2026
▲DSMB ReviewOlvi-VecTrial
IDMC recommended continuation of Phase 3 OnPrime/GOG-3076 trial without modification
platinum-resistant/refractory ovarian cancersource ↗
Jan 8, 2026
▼Equity OfferingCorporate
Pricing of $20.0 million underwritten public offering of common stock
Jan 2, 2026
2026
◆Timing GuidanceOlvi-VecPresentation
Additional systemic lung cancer data expected throughout 2026
lung cancers (SCLC and NSCLC)source ↗
2026
◆Dose Finding UpdateOlvi-VecTrial
Additional dose-finding updates from SCLC Phase 1b/2 trial expected throughout 2026
small cell lung cancersource ↗
Drug Pipeline Intelligence
C43
Pipeline Score $52M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 911)
Percentile RankGenelux Corporation carries a moderate pipeline score (43/100), with $1.1B risk-adjusted pipeline value, led by GL-ONC1 in Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GL-ONC1 Monoclonal antibody | Lung Cancer | Phase 1 | NCT01766739 | 17% | $610M | COMPLETED | 18 | - | - | Oct 24, 2024 | - | Oct 26, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Olvi-Vec Fast Track | platinum-resistant/refractory ovarian cancer | Phase 3 | 2026-03-19 | partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC) Read More | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Read More | |
Olvi-Vec Fast Track | platinum-resistant/refractory ovarian cancer | Phase 3 | 2026-03-19 | partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC) Read More | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Read More | |
Olvi-Vec Fast Track | platinum-resistant/refractory ovarian cancer | Phase 3 | 2026-03-19 | partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC) Read More | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GNLX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GNLX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GNLXGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux Corporation announced the publication of findings from its Phase 1b/2 VIRO-15 trial, highlighting the potential of Olvi-Vec to enhance chemotherapy sensitivity in platinum-resistant ovarian cancer. The study demonstrates that Olvi-Vec can modulate the tumor microenvironment and activate immune responses, supporting the ongoing Phase 3 OnPrime/GOG-3076 trial. The findings suggest a promising avenue for improving treatment outcomes in patients with limited options.
Read more →GNLXGenelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Genelux Corporation reported its first quarter financial results, revealing a cash position of $26.3 million expected to support operations into Q1 2027. The company is progressing with its Phase 3 OnPrime/GOG-3076 trial for Olvi-Vec in platinum-resistant ovarian cancer, with topline data anticipated in the second half of 2026. Additionally, Genelux is pursuing systemic lung cancer programs, with updates expected throughout 2026. However, the financial report noted a net loss of $8.9 million, indicating ongoing challenges as operational costs rise.
Read more →GNLXGenelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Genelux Corporation announced its fourth quarter and full year 2025 financial results while providing updates on clinical trials and operations. The company is poised for significant developments in 2026, with topline data from the Phase 3 OnPrime trial for Olvi-Vec expected in the second half of the year. Interim data has shown promise in lung cancer trials, and the recent appointment of Dr. Jason Litten as Chief Medical Officer aims to bolster the clinical development strategy. The company's financial position was strengthened by a successful stock offering, securing $18.5 million to fund ongoing operations.
Read more →GNLXGenelux Corporation to Participate in Upcoming Conferences
Genelux Corporation, a late clinical-stage immuno-oncology company, announced its participation in two upcoming conferences. The company is focused on developing next-generation oncolytic immunotherapies, with its lead product, Olvi-Vec, currently undergoing evaluation in several clinical trials for various cancer types. Webcasts of the events will be available on their Investor Relations website.
Read more →GNLXGenelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Genelux Corporation announced a virtual fireside chat featuring its CEO, CFO, and CMO on January 19, 2026. The chat will be hosted by Titan Partners and will discuss the company's developments in immuno-oncology. Genelux is focused on oncolytic immunotherapies, with ongoing clinical trials for its lead product, Olvi-Vec, in various cancer types.
Read more →GNLXGenelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
Genelux Corporation has announced the pricing of an underwritten public offering, aiming to raise approximately $20 million by selling 6,666,667 shares at $3.00 each. The proceeds will be allocated for general corporate purposes, including R&D and clinical trials. The offering is expected to close on January 9, 2026, pending customary conditions.
Read more →GNLXGenelux Corporation Announces Proposed Public Offering of Common Stock
Genelux Corporation has announced its proposed underwritten public offering of common stock, which includes a 30-day option for underwriters to purchase additional shares. This offering is part of its strategy to raise funds as the company advances its clinical-stage immuno-oncology programs. However, the offering is contingent on market conditions and customary closing requirements, leaving its success uncertain. The company specializes in developing oncolytic immunotherapies for challenging solid tumor types, enhancing its capital resources may support these efforts.
Read more →GNLX▼ -23.5%on this news· ran to -40% by day 3shared move
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
Genelux Corporation has reported encouraging interim data from its ongoing trials of Olvi-Vec for lung cancer treatment. In the Phase 1b/2 trial for small cell lung cancer (SCLC), two of three patients in the highest dose cohort showed significant tumor shrinkage. The Phase 2 trial for non-small cell lung cancer (NSCLC) also indicated anti-tumor activity. Further data is expected throughout 2026.
Read more →GNLX▼ -23.5%on this news· ran to -40% by day 3shared move
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer, effective January 2, 2026. Dr. Litten will lead clinical development and medical strategy for the company's immunotherapy, Olvi-Vec, which is undergoing pivotal trials for ovarian and lung cancer. His extensive experience in oncology drug development is expected to support Genelux's goals.
Read more →GNLX▲ +5.7%on this news
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
Genelux Corporation will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will represent the company during the event. Genelux is advancing its oncolytic immunotherapy, Olvi-Vec, through several clinical trials targeting difficult-to-treat cancers.
Read more →GNLX▼ -32.4%on this news
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation reported its third quarter 2025 financial results, highlighting progress in its lung cancer and ovarian cancer programs. The company anticipates interim data from its lung cancer studies in Q4 2025 and topline results from its Phase 3 ovarian cancer trial in the second half of 2026. Despite an increase in net loss and R&D expenses, Genelux remains optimistic about its pipeline and market opportunities.
Read more →GNLXGenelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
Genelux Corporation will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on September 9, 2025. The session will be moderated by Emily Bodnar and will include one-on-one meetings with institutional investors. Genelux is focused on developing oncolytic immunotherapies, with its lead product, Olvi-Vec, being evaluated in multiple clinical trials.
Read more →GNLX▼ -7%on this news
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation announced its financial results for the second quarter of 2025, reporting a net loss of $7.5 million. The company is working on advancing its candidate, Olvi-Vec, with key clinical readouts expected in the near future, especially for platinum-resistant ovarian cancer. Recent collaborations with the FDA could facilitate a traditional approval pathway for their trials. The appointment of Eric Groen as a new executive is anticipated to strengthen Genelux's leadership as it navigates upcoming developments.
Read more →GNLXGenelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen brings over two decades of experience in the life sciences industry, having previously served as General Counsel at Rani Therapeutics and spent 20 years at Amgen. His expertise is expected to enhance Genelux's strategic growth and development of its lead product, Olvi-Vec.
Read more →GNLX▼ -7.2%on this news· ran to +18% by day 3
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation announced its financial results for the first quarter of 2025, reporting a net loss of $7.5 million while highlighting progress in its clinical programs. The company received positive regulatory feedback from the FDA regarding its Olvi-Vec treatment for platinum-resistant/refractory ovarian cancer and is seeing increased patient enrollment in trials for lung cancer. Genelux also strengthened its finances through a recent equity raise, allowing further advancement of its strategic initiatives amid ongoing clinical trials.
Read more →GNLX▲ +8.5%on this newsshared move
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Genelux Corporation will participate in a fireside chat at the Citizens Life Sciences Conference on May 8, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will discuss the company's clinical-stage programs, including trials for their oncolytic immunotherapy, Olvi-Vec. The event will be webcasted, and one-on-one meetings will be available for institutional investors.
Read more →GNLXGenelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Genelux Corporation announced its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical development. The company has reached alignment with the FDA regarding approval pathways for its candidate Olvi-Vec in treating platinum-resistant ovarian cancer, while also reporting promising preliminary data from ongoing trials in small-cell lung cancer. Additionally, Genelux closed a $10.5 million underwritten offering that enhances its financial position. Despite these positive developments, the company reported a net loss of $29.9 million for the year.
Read more →GNLX▼ -12.6%on this newsshared move
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
Genelux Corporation has announced a $10.5 million underwritten offering of 3 million shares at $3.50 each. The proceeds will be utilized for working capital and the clinical development of their product, Olvi-Vec. The offering is expected to close on March 26, 2025, pending customary conditions. Titan Partners Group is the sole bookrunner for this offering.
Read more →GNLX▼ -12.6%on this newsshared move
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
Genelux Corporation has successfully engaged with the FDA regarding the approval pathway for Olvi-Vec, aimed at treating platinum resistant/refractory ovarian cancer. The FDA indicated that data from the ongoing Phase 3 trial, OnPrime/GOG-3076, could support traditional approval if a clinically meaningful progression-free survival advantage is demonstrated. Genelux plans to submit a marketing application based on interim analysis results.
Read more →GNLX▼ -12.6%on this newsshared move
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
Genelux Corporation and Newsoara BioPharma have reported promising preliminary results from their Phase 1b/2 trial of Olvi-Vec in patients with advanced small-cell lung cancer. The drug demonstrated a 71% disease control rate, with notable tumor reductions in participants. The trial continues to assess safety and efficacy as it progresses.
Read more →GNLX▼ -10.6%on this news
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation has announced the appointment of Matthew Pulisic as its new Chief Financial Officer, effective January 30, 2025. Pulisic brings over 19 years of finance and commercial experience in the biopharmaceutical industry, having held senior leadership roles at companies like Arrowhead Pharmaceuticals and Amgen. His expertise is expected to enhance Genelux's financial strategies and support the anticipated launch of the company’s product, Olvi-Vec. Along with his appointment, Pulisic received an inducement award for stock options, reflecting alignment with the company's growth objectives.
Read more →GNLX▼ -7.5%on this news
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation (NASDAQ: GNLX) will have its President and CEO, Thomas Zindrick, participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. This session will explore the company's clinical programs, including trials for its lead candidate, Olvi-Vec, across multiple cancer types. The event signifies Genelux's efforts to keep investors informed regarding its ongoing research and development initiatives.
Read more →GNLXGenelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation has reported its financial results for the third quarter of 2024 and provided updates on its lung cancer trials. The company initiated a Phase 2 trial for recurrent advanced non-small cell lung cancer and is actively enrolling participants in other ongoing trials for small cell lung cancer. Despite a reported net loss of $6.5 million, Genelux has sufficient capital to fund operations into 2026. The CEO expressed confidence in the clinical potential of their lead asset, Olvi-Vec, in advancing cancer therapies.
Read more →GNLXGenelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Genelux Corporation announced its participation in the Guggenheim Inaugural Healthcare Innovation Conference, scheduled for November 11-13, 2024, in Boston, Massachusetts. Thomas Zindrick, the company's President, CEO, and Chairman, will present in a fireside chat discussing clinical-stage programs, recent announcements, and future milestones. Additionally, Genelux plans to hold one-on-one meetings with institutional investors during the conference. A webcast of the event will be made accessible, along with an archived replay for later viewing.
Read more →GNLXGenelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
Genelux Corporation has announced that the first patient has been dosed in its Phase 2 trial (VIRO-25) evaluating the efficacy and safety of Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC). This trial is significant as it represents the second indication for Olvi-Vec via systemic delivery. The trial aims to compare Olvi-Vec combined with chemotherapy and immune checkpoint inhibitors against docetaxel. Results of previous trials have indicated that Olvi-Vec is generally well tolerated and suggests possible clinical benefits. An interim readout is anticipated by mid-2025.
Read more →GNLXGenelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Genelux Corporation (NASDAQ: GNLX) announced that its President and CEO, Thomas Zindrick, will participate in the upcoming 2024 Maxim Healthcare Virtual Summit from October 15-17, 2024. During the summit, Zindrick is set to engage in a fireside chat focusing on the company's clinical-stage programs and recent developments. This event represents a significant opportunity for Genelux to showcase its advancements in immuno-oncology.
Read more →GNLXGenelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux Corporation (NASDAQ: GNLX) announced that its President and CEO, Thomas Zindrick, will present at the H.C. Wainwright Global Healthcare Conference on September 11, 2024. The discussion will highlight the company's clinical-stage programs and recent announcements. Additionally, Genelux will hold virtual one-on-one meetings for institutional investors during the conference. This engagement reflects the company's commitment to keeping investors informed about its progress and upcoming milestones.
Read more →GNLXGenelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation reported its second-quarter 2024 financial results and provided updates on business operations, highlighting significant ongoing clinical trials. The company successfully completed key financing, ensuring funding for ongoing Phase 3 trials in platinum-resistant ovarian cancer. Interim results from other trials involving Olvi-Vec are expected within the next 12 months. Despite a net loss of $6.6 million for the quarter, the firm remains optimistic about its future clinical prospects.
Read more →GNLXGenelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
Genelux Corporation is set to participate in a fireside chat at BTIG's Virtual Biotechnology Conference 2024. Thomas Zindrick, the company's President, CEO, and Chairman, will discuss various topics, including clinical-stage programs and recent announcements. This event is scheduled for August 6, 2024, at 12:00 p.m. ET, and will be led by Kaveri Pohlman, a BTIG Biotechnology Analyst.
Read more →GNLX▼ -43%on this news
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation announced the pricing of an underwritten offering of approximately $27.5 million, comprising 6,875,000 shares of common stock and warrants. The offering is expected to support the clinical development of their leading product candidate, Olvi-Vec, through early 2026. Results from the Phase 3 trial for Olvi-Vec are anticipated in the second half of 2025. The offering is subject to closing conditions and market conditions, with a potential 30-day option for underwriters to purchase additional shares.
Read more →GNLX▼ -5.3%on this news· ran to -46% by day 1shared move
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation has announced the commencement of a public offering of its common stock and accompanying warrants. This offering aims to expand the company's financial resources for further development of its pipeline, particularly in immuno-oncology therapies. Guggenheim Securities is the sole book-running manager, while Newbridge Securities Corporation acts as co-manager. However, the offering's completion is subject to market conditions, and there is no guarantee regarding its size or terms.
Read more →GNLX▲ +6.1%on this news
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation has reported its financial results for the first quarter of 2024, revealing a decreased net loss compared to the previous year. The company continues to advance its pivotal Phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer and is set to initiate a Phase 2 trial for recurrent non-small cell lung cancer. Additionally, Genelux is actively enrolling patients in several ongoing trials and has filed a shelf registration statement, aiming to enhance its capital resources. Despite rising operational expenses, the company maintains a positive outlook on its clinical progress and cash runway.
Read more →GNLX▼ -18.5%on this news
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Genelux Corporation reported its fourth quarter and full year 2023 financial results, showcasing progress in its clinical pipeline, particularly with Olvi-Vec across various cancer treatments. The company is actively enrolling patients in its pivotal Phase 3 trial for platinum resistant/refractory ovarian cancer, with topline results expected in the second half of 2025. Genelux also plans to initiate a Phase 2 trial in non-small cell lung cancer in the first half of 2024. Despite a net loss increase compared to 2022, the company's cash position has strengthened significantly, providing financial stability for ongoing trials.
Read more →GNLXGenelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Genelux Corporation announced that the FDA granted Fast Track designation for Olvi-Vec, a treatment for platinum resistant/refractory ovarian cancer. This designation will expedite the drug's development and review process, as Genelux continues to enroll patients in its Phase 3 OnPrime study. The company's Phase 2 trial previously demonstrated successful clinical outcomes in reversing platinum resistance, further supporting the efficacy of Olvi-Vec. The Fast Track designation emphasizes the drug's potential to address significant unmet needs in cancer treatment.
Read more →GNLXGenelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
Genelux Corporation reported its third quarter 2023 financial results, highlighting the hiring of Lourie Zak as the new CFO. The company continues its clinical focus on Olvi-Vec, with ongoing trials for treatments in small cell and non-small cell lung cancer. Despite having $29.9 million in cash, the company reported a net loss of $5.3 million and faces potential funding delays from an investor. The overall outlook remains cautiously optimistic as the company seeks to advance its pivotal Phase 3 study in ovarian cancer and expand its executive team.
Read more →GNLXGenelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Genelux Corporation has granted stock options to new employees as part of its 2023 Inducement Plan under Nasdaq Listing Rule 5635(c)(4). The Board approved a total of 444,300 shares to be offered as inducement awards, aimed at integrating new talent into the company. Key positions receiving these options include the Chief Financial Officer and the new Head of Quality. Each stock option has an exercise price based on the company's stock price on the grant date and will vest over a four-year period.
Read more →GNLXGenelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
Genelux Corporation reported financial results for Q2 2023, highlighting $51 million raised through private placements, positioning it to fund operations into early 2026. The company announced positive Phase 2 data for its cancer treatment, Olvi-Vec, published in JAMA Oncology. Additionally, Genelux joined the Russell 3000 and 2000 indices, reflecting its growing market presence. However, the company reported an increased net loss compared to the previous year, alongside rising R&D expenses attributed to ongoing clinical trials.
Read more →GNLXGenelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
Genelux Corporation announced that its President and CEO, Thomas Zindrick, will participate in a fireside chat at BTIG's Virtual Biotechnology Conference on August 8, 2023. The discussion will cover the company's clinical-stage programs, recent announcements, and future milestones. This event may provide valuable insights into Genelux's progress and developments in immuno-oncology.
Read more →GNLX▼ -10.8%on this news· ran to -25% by day 1
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
Genelux Corporation has announced key management promotions and new hires to strengthen its senior leadership team. Joseph Cappello and Tony Yu have been promoted to CTO and SVP of Clinical Development, respectively, reflecting their significant contributions to the company. Ralph Smalling and Caroline Jewett have joined as Head of Regulatory and Head of Quality, respectively, bringing a wealth of industry experience. The company is focusing on its ongoing Phase 3 OnPrime trial and the possibility of a biologics license application.
Read more →GNLXGenelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
Genelux Corporation announced the publication of positive results from a Phase 1 trial of Olvi-Vec, an oncolytic virus therapy, administered intrapleurally to patients with malignant pleural effusions. The trial reported a median overall survival of 19.5 months, with no dose-limiting toxicities encountered. This study, conducted at Memorial Sloan Kettering Cancer Center, provides important evidence supporting the immune-activating effects of Olvi-Vec and its potential efficacy in treating diverse cancer types indicated in the trial.
Read more →GNLXGenelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
Genelux Corporation and TVAX Biomedical, Inc. announced the granting of a United States patent for a combination therapy that integrates vaccine-enhanced adoptive T cell therapy with oncolytic virus therapy, licensed exclusively to their joint venture, V2ACT Therapeutics, LLC. This patent provides significant intellectual property protection until 2036 and supports the clinical potential of V2ACT Immunotherapy for treating various cancers. Both Genelux and TVAX are involved in the development of advanced therapies aimed at improving clinical outcomes for patients with hard-to-treat solid tumors.
Read more →GNLX▼ -7.1%on this news
Genelux Corporation Set to Join the Russell 3000 and Russell 2000 Indexes Effective June 26, 2023
Genelux Corporation announced that it will be added to the Russell 3000 and Russell 2000 Indexes after the annual reconstitution on June 26, 2023. This change reflects the company's recent clinical successes and growth potential, particularly related to its oncolytic virus platform, Olvi-Vec. The inclusion is expected to boost investor interest and expand institutional ownership, resulting in increased liquidity for Genelux's shares. The recognition also aligns with a trend of growth within the health care sector, as more companies transition from small-cap to larger market capitalizations.
Read more →GNLX▲ +7.6%on this news· ran to +30% by day 3
Genelux Corporation Announces $18 Million Private Placement
Genelux Corporation announced a private placement of 900,000 shares at $20 per share, raising about $18 million. Led by existing investors, this funding follows a previous $33 million placement and will extend the company’s cash runway. Proceeds will be used for manufacturing expansion and advancing its clinical programs, including a Phase 3 trial for Olvi-Vec in ovarian cancer patients. The initial closing is expected by June 20, 2023, with additional funds to follow by November 15, 2023.
Read more →GNLX▲ +6.6%on this news· ran to +17% by day 3
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
Genelux Corporation announced the publication of positive topline data from its Phase 2 VIRO-15 trial of Olvimulogene Nanivacirepvec (Olvi-Vec) in JAMA Oncology. The trial showed a significant objective response rate of 54% and a median progression-free survival of 11.0 months among heavily treated patients with platinum-resistant or refractory ovarian cancer. The findings are notable due to the substantial unmet medical need in this patient population. Additionally, the trial demonstrated a favorable safety profile, suggesting Olvi-Vec's potential as an effective treatment option.
Read more →GNLX▼ -9.1%on this news
Genelux Corporation Announces $33 Million Private Placement
Genelux Corporation, a clinical-stage immuno-oncology company, announced a private placement of approximately $33 million through the sale of 1,665,247 shares at $20 each. The proceeds are intended to enhance its financial position and support ongoing clinical trials, particularly a Phase 3 trial for Olvi-Vec targeting platinum-resistant ovarian cancer. The initial closing is expected soon, with an additional investment committed by November 2023. However, the securities involved are not registered under federal securities laws, posing limitations on their sale.
Read more →GNLXGenelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
Genelux Corporation, a late clinical-stage biopharmaceutical company, will ring the Nasdaq opening bell on March 29, 2023, to celebrate its recent IPO. This event signifies a milestone for Genelux as it aims to establish itself in the immunotherapy space, particularly for aggressive solid tumors. CEO Thomas Zindrick expressed excitement about this achievement and the ongoing support from stakeholders. The opening ceremony will be broadcast live and shared across various social media platforms.
Read more →GNLXGenelux Corporation Announces Pricing of Initial Public Offering
Genelux Corporation has announced the pricing of its initial public offering, offering 2,500,000 shares at $6.00 each for total proceeds of approximately $15 million. The shares are set to begin trading on the Nasdaq Capital Market under the ticker symbol GNLX on January 26, 2023, pending final approval. The offering is also contingent on customary closing conditions, with underwriters granted an option to purchase additional shares. This marks a significant milestone for Genelux, which focuses on developing oncolytic viral immunotherapies for challenging solid tumor types.
Read more →GNLXGenelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy Trial will be conducted as a collaboration between Genelux and The Gynecological Oncological Group (GOG) WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLO
Read more →GNLXGenelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions
First two patients dosed in Phase 1b Trial in Ovarian Cancer at Florida Hospital Cancer Institute (FHCI) First three patients dosed in Phase 1b Trial in Solid Organ Cancers at Moores Cancer Center at UC San Diego Health Results of both trials represent significant near-term mil
Read more →GNLXGenelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma
Data Demonstrate Favorable Safety Profile and Anti-Tumor Activity Results to be Presented at ASCO Annual Meeting 2015 During Two Poster Presentations SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the devel
Read more →GNLXGenelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that two posters supporting the ongoing clinical development of its lead clinical
Read more →GNLXGenelux Appoints George Vandeman and Thomas Zindrick to Board of Directors
SAN DIEGO, CA--(Marketwired - May 28, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced the appointment of Mr. George Vandeman, long-time Amgen executive, and Thomas Zind
Read more →GNLXGenelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board
SAN DIEGO, CA--(Marketwired - May 12, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced that Aladar Szalay, PhD has chosen to retire from the positions of Chairman, Presi
Read more →GNLXGenelux Corporation CEO, Dr. Aladar A. Szalay, to Give a Keynote Lecture at the 8th International Conference on Oncolytic Virus Therapeutics
SAN DIEGO, CA--(Marketwired - Apr 8, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and diagnostics, today announced that its Founder and CEO, Dr. Aladar A. Szalay, a respected researcher and thought leader
Read more →GNLXGenelux Corporation Appoints John D. Prunty Chief Financial Officer
SAN DIEGO, CA--(Marketwired - Feb 11, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, announced today that, after a lengthy executive search process, its Board of Directors has appoint
Read more →GNLXGenelux Corporation Appoints Stefan M. Manth, MD, as President & CEO, Genelux Europe
SAN DIEGO, CA--(Marketwired - Jun 27, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced its Board of Directors has appointed Stefan M. Manth, MD, to lead Genelux Europe,
Read more →GNLXGenelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
SAN DIEGO, CA--(Marketwired - May 30, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today announced that it will present two posters at the American Society of Clinical Oncolo
Read more →GNLXGenelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers
SAN DIEGO, CA--(Marketwire - Nov 1, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics, announced early results of the first patient cohort treated in a Phase I/II clinical t
Read more →GNLXGenelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients
SAN DIEGO, CA--(Marketwire - Jun 28, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagnostics for cancer, today announced the start of a ground-breaking clinical study in
Read more →GNLXGenelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1
SAN DIEGO, CA--(Marketwire - Jun 14, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagnostics for cancer, today announced that the first patient has been dosed in a Phase
Read more →GNLXGenelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers
SAN DIEGO, CA--(Marketwire - May 31, 2012) - Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today an
Read more →GNLXGenelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
SAN DIEGO, CA--(Marketwire - May 30, 2012) - Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today a
Read more →Competitive Position
How GNLX ranks across every disease it competes inCompetitive Position is a premium feature
See how GNLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial